Skip to content

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

fMRI and Genotype Markers of Antidepressant Side Effects and Response in Young Adults Compare to Older Adults

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00707863
Enrollment
17
Registered
2008-07-01
Start date
2008-05-31
Completion date
2012-12-31
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression

Keywords

Escitalopram, Lexapro, fMRI, pictures

Brief summary

The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain

Detailed description

This study will measure the activity in different parts of the brain, while the patients are seeing some pictures, using Magnetic Resonance Imaging (MRI) scan. For this study three MRI scans will be conducted. One before the patient begins on any medication, one during the study after 3 weeks of treatment and one after six more weeks of treatment with a standard antidepressant called Escitalopram(trade name: Lexapro).

Interventions

DRUGEscitalopram

10 mg of Escitalopram by mouth once a day for 8 weeks

Sponsors

National Alliance for Research on Schizophrenia and Depression
CollaboratorOTHER
Indiana University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Ages 18-50 years and able to give voluntary informed consent. * Satisfy criteria for Major Depressive Disorder (MDD) and current depressed episode using the Mini International Neuropsychiatric Interview (M.I.N.I.). * 17-item Hamilton Depression Rating Scale (HDRS) score \> 18. * Satisfy criteria to undergo an MRI scan based on MRI screening questionnaire. * Able to be managed as outpatients for initial assessment and during treatment as ascertained by the following - * Symptoms not worsening by more than 10 points on the HDRS during the course of the study. * No danger to self or others.

Exclusion criteria

* Meeting DSM-IV criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar disorder, atypical psychosis, mental retardation, or organic mental (including organic mood) disorder. * On monoamine oxidase inhibitors in the past 2 weeks. * History of narrow angle glaucoma. * Lack of response of the current episode of depression to two or more adequate courses of antidepressant therapy at a clinically appropriate dose for a minimum of 4 weeks or, in the judgment of the investigator, the patient meets criteria for treatment-resistant depression. * Use of neuroleptic in the past 2 weeks. * Use of antidepressants in the past 2 weeks. If on fluoxetine in the past, then should not have been on this medication for 4 weeks. * Use of mood stabilizers in the past 2 weeks. * Use of benzodiazepines in the past 2 weeks. * Acutely suicidal or homicidal or requiring inpatient treatment. * Meeting DSM-IV criteria for other substance dependence within the past year, except caffeine or nicotine. The criteria will be evaluated by interview and urinary toxicology screening initially and on test days. * Use of alcohol in the past 1 week. * No serious medical or neurological illness as assessed by physical examination and laboratory examination including CBC and blood chemistry. * Current pregnancy or breast-feeding. * Metallic implants. * Previously known positive HIV blood test as reported by the subject.

Design outcomes

Primary

MeasureTime frameDescription
17-item Hamilton Depression Rating Scale (HAM-D)Baseline and 8 weeksStandard scale for depression used in clinical trials. Range: 0 - 54. A score of 0-7 is considered to be normal. 8 - 13 mild depression. Scores of 20 or higher indicate moderate -severe depression.

Countries

United States

Participant flow

Participants by arm

ArmCount
Depressed Subjects Age: 18 - 25 Yrs
Subjects receiving Escitalopram (trade name: Lexapro) that are in the age range of 18-25 Escitalopram: 10 mg of Escitalopram by mouth once a day for 8 weeks
6
Depressed Subjects Age: 16 - 50 Yrs
Subjects receiving Escitalopram (trade name: Lexapro) in the age range of 26-50 Escitalopram: 10 mg of Escitalopram by mouth once a day for 8 weeks
11
Total17

Baseline characteristics

CharacteristicDepressed Subjects Age: 16 - 50 YrsDepressed Subjects Age: 18 - 25 YrsTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
11 Participants6 Participants17 Participants
Age, Continuous34 years
STANDARD_DEVIATION 6
22 years
STANDARD_DEVIATION 1
30 years
STANDARD_DEVIATION 7
Region of Enrollment
United States
11 participants6 participants17 participants
Sex: Female, Male
Female
9 Participants5 Participants14 Participants
Sex: Female, Male
Male
2 Participants1 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
5 / 611 / 11
serious
Total, serious adverse events
0 / 60 / 11

Outcome results

Primary

17-item Hamilton Depression Rating Scale (HAM-D)

Standard scale for depression used in clinical trials. Range: 0 - 54. A score of 0-7 is considered to be normal. 8 - 13 mild depression. Scores of 20 or higher indicate moderate -severe depression.

Time frame: Baseline and 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Depressed Subjects Age: 18 - 25 Yrs17-item Hamilton Depression Rating Scale (HAM-D)Baseline 17-item HAM-D18 units on a scaleStandard Deviation 1
Depressed Subjects Age: 18 - 25 Yrs17-item Hamilton Depression Rating Scale (HAM-D)Post-8 week treatment 17-item HAM-D6 units on a scaleStandard Deviation 3
Depressed Subjects Age: 16 - 50 Yrs17-item Hamilton Depression Rating Scale (HAM-D)Baseline 17-item HAM-D19 units on a scaleStandard Deviation 1
Depressed Subjects Age: 16 - 50 Yrs17-item Hamilton Depression Rating Scale (HAM-D)Post-8 week treatment 17-item HAM-D6 units on a scaleStandard Deviation 4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026